Marché mondial du traitement des infections des voies respiratoires inférieures – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché du traitement des infections des voies respiratoires inférieures

La pneumonie est un terme fréquemment utilisé pour décrire les maladies des voies respiratoires inférieures. La grippe, la bronchite, la bronchiolite et la pneumonie font partie des maladies les plus répandues, bien qu'elles ne soient pas toutes classées de la même manière. Partout dans le monde, les infections des voies respiratoires inférieures sont la principale cause de maladie et de décès chez les enfants et les adultes. Pour le traitement des patients gravement malades atteints du syndrome de détresse respiratoire aiguë, de nouveaux traitements pulmonaires sont explorés par de nombreux instituts de recherche (ARDS).

Français Data Bridge Market Research analyse que le marché du traitement des infections des voies respiratoires inférieures, qui était de 50,22 milliards USD en 2022, devrait atteindre 89,57 millions USD d'ici 2030, à un TCAC de 7,5 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement des infections des voies respiratoires inférieures  

Market Definition

Infections that affect the airways (below the level of the larynx), such as the trachea and alveolar sacs, are referred to as lower respiratory tract infections (LRTI). LRTI can be categorized in several different ways. While pneumonia is an example of a severe infection that damages the alveolar sacs, severe infections that impact the airways include acute bronchitis, bronchiolitis, and the flu.

Lower Respiratory Tract Infection Treatment Market Dynamics

Drivers

• The rising prevalence of chronic respiratory disorders will drive the growth of the market

The rising prevalence of chronic respiratory disorders such as asthma, chronic pulmonary fibrosis, pulmonary hypertension, and occupational lung disease drive the respiratory tract infection market forward. For example, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyperresponsiveness. These are certain factors that will propel the market growth.

• The rise in the geriatric population will drive the market growth

The market's rise is anticipated to be aided by the growing geriatric population during the projection period of 2023-2030. The World Health Organization (WHO) projects that by 2050, there will be approximately 2 billion geriatric people globally, up from an estimated 524 million in 2010. Geriatrics are more likely to have lower respiratory tract infections because of their weakened immune systems, which is predicted to increase the market's growth rate.

Opportunities

• Collaborations and partnerships will act as an opportunity

Numerous organizations, institutions, and agencies are working together to enhance diagnostic and medical care to minimize the burden of respiratory illnesses on people worldwide. For instance, to fight chronic respiratory disorders, the World Health Organization (WHO) encouraged the creation of the Global Alliance against Chronic Respiratory Diseases (GARD). The primary objectives of GARD are to create simple and economic chronic respiratory disease (CRD) solutions and to persuade nations to undertake CRD prevention and health promotion measures. These are the certain reasons which will boost the market expansion.

Restraints/Challenges

• Side-effects associated with lower respiratory tract infection treatment

Overprescribing antibiotics is associated with a higher risk of adverse effects, frequent follow-up appointments, and a greater medicalization of self-limiting illnesses. Overprescribing antibiotics is a significant problem in primary care since viruses frequently cause infections. Almost 90% of all antibiotic prescriptions issued by general practitioners are for respiratory system infections.

This lower respiratory tract infection treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lower respiratory tract infection treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Biapenem was approved by the FDA for the treatment of intra-abdominal, lower respiratory, and severe urinary tract infections. Biapenem is typically given to patients with severe urinary tract infections, lower respiratory infections, or intra-abdominal infections. It's a parenterally administered carbapenem antibacterial medication. Biapen's dosage is considerably less than that of other carbapenems, though.

Global Lower Respiratory Tract Infection Treatment Market Scope

The lower respiratory tract infection treatment market is segmented on the basis of mode of transmission, type of infection, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Transmission

• Hospital Acquired
• Ventilator Acquired
• Community Acquired

Type of Infection

• Pneumonia
• Bronchitis
• Influenza
• Tuberculosis
• Others

Route of Administration

• Oral
• Parenteral
• Others

Diagnosis

• Mucus Samples
• Blood Tests
• Chest X-rays
• Pulse Oximetry

Treatment

• Medication
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Acetaminophen
• Bronchodilator inhaler
• Antibiotics
• Others
• Intravenous Fluids
• Humidified Oxygen, Vaccines
• Vaccines

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Lower Respiratory Tract Infection Treatment Market Regional Analysis/Insights

The lower respiratory tract infection treatment market is analysed and market size insights and trends are provided by country, mode of transmission, type of infection, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the lower respiratory tract infection treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the lower respiratory tract infection treatment market due to the region's growing geriatric population, immune-compromised seniors, and multi-drug resistant bacterial infections in youngsters. The presence of significant key players and rising healthcare costs will further contribute to the market's rapid expansion in this area.

Asia-Pacific is expected to grow at the highest rate from 2023 to 2030 because unhealthy lifestyles are becoming more common in this area. Expanding the healthcare infrastructure and increasing patient awareness will also boost the market's growth rate in this area.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Lower Respiratory Tract Infection Treatment Market Share Analysis

Le paysage concurrentiel du marché du traitement des infections des voies respiratoires inférieures fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du traitement des infections des voies respiratoires inférieures.

Certains des principaux acteurs opérant sur le marché du traitement des infections des voies respiratoires inférieures sont :

• F. Hoffmann-La Roche SA (Suisse)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Merck & Co., Inc. (États-Unis)
• Société Bristol-Myers Squibb (États-Unis)
• Abbott (États-Unis)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Allergan (Irlande)
• Eli Lilly and Company (États-Unis)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• SHIONOGI & Co., Ltd. (Japon)
• AbbVie Inc. (États-Unis)

SKU-55897